OpenURL Connection Search

Select item for more details and to access through your institution.

Autologous stem cell transplantation is infrequently utilized but associated with improved overall survival in elderly patients with mantle cell lymphoma.
Published in:
Hematological Oncology, 2017, v. 35, p. 357, doi. 10.1002/hon.2439_112
By:
- Cohen, J.B.;
- Greenwell, I.B.;
- Liu, Y.;
- Behera, M.;
- Flowers, C.R.
Publication type:
Article
VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY.
Published in:
Hematological Oncology, 2017, v. 35, p. 90, doi. 10.1002/hon.2437_78
By:
- Swinnen, L.J.;
- Flowers, C.R.;
- Wang, D.;
- Reid, E.;
- Fowler, N.;
- Cordero, J.;
- Dunbar, M.;
- Enschede, S.;
- Nolan, C.;
- Petrich, A.M.;
- Ross, J.;
- Salem, A.H.;
- Verdugo, M.;
- Wong, S.;
- Zhou, L.;
- Kozloff, M.;
- Nastoupil, L.;
- Vos, S.
Publication type:
Article
CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL.
Published in:
Hematological Oncology, 2017, v. 35, p. 112, doi. 10.1002/hon.2437_101
By:
- Nastoupil, L.;
- Lunning, M.A.;
- Vose, J.M.;
- Schreeder, M.T.;
- Siddiqi, T.;
- Flowers, C.R.;
- Cohen, J.B.;
- Burger, J.A.;
- Wierda, W.G.;
- O'Brien, S.;
- Sportelli, P.;
- Miskin, H.P.;
- Purdom, M.A.;
- Weiss, M.S.;
- Fowler, N.H.
Publication type:
Article
AUTOLOGOUS TRANSPLANTATION IMPROVES SURVIVAL IN PATIENTS WITH FOLLICULAR LYMPHOMA EXPERIENCING EARLY THERAPY FAILURE AFTER FRONTLINE CHEMOIMMUNOTHERAPY: AN NLCS AND CIBMTR ANALYSIS.
Published in:
Hematological Oncology, 2017, v. 35, p. 222, doi. 10.1002/hon.2438_86
By:
- Casulo, C.;
- Friedberg, J.W.;
- Ahn, K.W.;
- Flowers, C.R.;
- DiGilio, A.
Publication type:
Article
Impact of post-transplant lymphoproliferative disorder subtype on survival.
Published in:
Hematological Oncology, 2017, v. 35, p. 347, doi. 10.1002/hon.2439_97
By:
- Koff, J.L.;
- Li, J.;
- Zhang, X.A.;
- Switchenko, J.M.;
- Flowers, C.R.;
- Waller, E.K.
Publication type:
Article
BEYOND MAXIMUM GRADE: A NOVEL, LONGITUDINAL TOXICITY OVER TIME (TOXT) ADVERSE EVENT ANALYSIS OF LENALIDOMIDE IN FOLLICULAR LYMPHOMA IN CALGB 50401 (ALLIANCE).
Published in:
Hematological Oncology, 2017, v. 35, p. 213, doi. 10.1002/hon.2438_78
By:
- Thanarajasingam, G.;
- Dueck, A.C.;
- Novotny, P.J.;
- Witzig, T.E.;
- Habermann, T.M.;
- Nowakowski, G.S.;
- Flowers, C.R.;
- Bartlett, N.L.;
- Blum, K.A.;
- Pitcher, B.N.;
- Jung, S.;
- Atherton, P.J.;
- Tan, A.D.;
- Sloan, J.A.;
- Leonard, J.P.
Publication type:
Article
POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FL OR DLBCL: UPDATED RESULTS OF A PHASE 1B/2 STUDY.
Published in:
Hematological Oncology, 2017, v. 35, p. 271, doi. 10.1002/hon.2438_144
By:
- Matasar, M.;
- Herrera, A.F.;
- Kamdar, M.;
- Mehta, A.;
- Assouline, S.;
- Fleury, I.;
- Kim, T.M.;
- Kim, W.S.;
- Bosch, F.;
- Radford, J.;
- Flowers, C.R.;
- Bu, L.;
- Hong, W.;
- Sehn, L.H.
Publication type:
Article

Found: 7

Autologous stem cell transplantation is infrequently utilized but associated with improved overall survival in elderly patients with mantle cell lymphoma.

VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY.

CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL.

AUTOLOGOUS TRANSPLANTATION IMPROVES SURVIVAL IN PATIENTS WITH FOLLICULAR LYMPHOMA EXPERIENCING EARLY THERAPY FAILURE AFTER FRONTLINE CHEMOIMMUNOTHERAPY: AN NLCS AND CIBMTR ANALYSIS.

Impact of post-transplant lymphoproliferative disorder subtype on survival.

BEYOND MAXIMUM GRADE: A NOVEL, LONGITUDINAL TOXICITY OVER TIME (TOXT) ADVERSE EVENT ANALYSIS OF LENALIDOMIDE IN FOLLICULAR LYMPHOMA IN CALGB 50401 (ALLIANCE).

POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FL OR DLBCL: UPDATED RESULTS OF A PHASE 1B/2 STUDY.